TME Pharma
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes.
Products
Some Spiegelmer candidates were in clinical trials.A Spiegelmer was under development as a combination therapy for a number of cancer indications. NOX-A12 targets CXCL12, a key chemokine protein. Favorable results were reported in October 2018 during the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York, NY, USA.
A different Spiegelmer was tested for the treatment of progressive diabetic nephropathy. Favorable results were reported in June 2014 in a company press release. NOX-E36 targets MCP-1, also called CCL2.
A third Spiegelmer was in a clinical trial for the treatment of anemia of chronic disease.